Ensoma Stock

www.ensoma.comHealthcareFounded: 2019

Ensoma, founded in 2019, is a biotechnology company with the goal of expanding the reach of the curative power of genomic medicine by seeking to pioneer a next-generation in vivo approach using its Engenious vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies aim to be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. Ensoma is headquartered in Boston, Massachusetts.

Register for Details

For more details on financing and valuation for Ensoma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Ensoma.

Register Today

Ensoma investors also invested in these private companies

Takeda Ventures
Bill & Melinda Gates Foundation
RIT Capital Partners
Mirae Asset Global Investments
Cormorant Asset Management
Delos Capital
Catalio Capital Management
SymBiosis Capital Management
Arix Bioscience
Bioluminescence Ventures
Gilead Sciences
Solasta Ventures
5AM Ventures
Alexandria Venture Investments
Fred Hutchinson Cancer Research Center
Kite Pharma


Management Team

Emile Nuwaysir Ph.D
Chief Executive Officer & President
Min Wang Ph.D
President & Chief Operating Officer
Daniel Leblanc
Chief Technology Officer
Robert Peters Ph.D
Chief Scientific Officer
Naina Bhasin Ph.D
Chief Business Officer
André Lieber Ph.D
Co-Founder & Scientific Advisor

Board Members

Kush Parmar Ph.D
5AM Ventures
Mark Chin
Arix Bioscience
Paula Soteropoulos
5AM Ventures
Stephen Knight MD
F-Prime Capital

Other companies like Ensoma in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


Ensoma, a genomic medicines company developing one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the closing of an extension of its Series B financing by $50 million, bringing the total size of the funding round to $135 million.
The concept of in vivo cell therapies moves two steps ahead with the announcements that Ensoma raised $85 million in a series B financing round and added a Cas12a gene editing system to its toolbox through the acquisition of Twelve Bio.